BofA warns Fed risks policy mistake with early rate cuts
BOSTON - PureTech Health plc (NASDAQ:PRTC, LSE:PRTC) presented data from its Phase 2b ELEVATE IPF trial at the 2025 IPF Summit this week, positioning deupirfenidone as a potential new treatment for idiopathic pulmonary fibrosis (IPF).
The company reported that deupirfenidone demonstrated a statistically significant reduction in lung function decline at 26 weeks compared to placebo. Patients receiving deupirfenidone 825 mg three times daily showed a decline of -21.5 mL in forced vital capacity (FVC) versus -112.5 mL for those on placebo.
The treatment effect with deupirfenidone was approximately 50% greater than that of pirfenidone, one of two currently FDA-approved treatments for IPF. Initial data from an ongoing open-label extension study indicated the treatment effect was sustained through at least 52 weeks.
PureTech also shared findings from patient interviews, noting that 69% of participants preferred treatments offering greater efficacy over improved tolerability.
"The ELEVATE IPF trial stands out for its thoughtful design and execution," said Toby Maher, MD, PhD, Professor of Medicine at Keck School of Medicine and lead investigator in the trial, according to the company statement.
Deupirfenidone will be advanced by Celea Therapeutics, PureTech’s newly launched entity focused on respiratory diseases. Celea is led by Sven Dethlefs, PhD, who brings experience in respiratory therapeutics.
IPF is a rare, progressive lung disease characterized by irreversible scarring of lung tissue. Current treatments offer limited efficacy in slowing lung function decline, with only approximately 25% of IPF patients in the U.S. receiving either of the two approved drugs.
Additional data from the open-label extension study will be presented at the European Respiratory Society International Congress in September 2025, according to the press release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.